Share
Dr. Bobby Gaspar
Eligo Bioscience, a biotechnology company focused on expanding gene-editing targets by delivering genetic medicines to the microbiome, announced the appointment of Dr. Bobby Gaspar, CEO of Orchard Therapeutics, as the new chair of its board of directors.
This appointment comes shortly after the company’s breakthrough publication in Nature, highlighting its innovative gene-editing approach to targeting the microbiome.
Xavier Duportet, CEO and co-founder of Eligo, welcomed Dr. Gaspar, praising his leadership in transforming genetic medicine from concept to commercialization at Orchard Therapeutics. Dr. Gaspar, a pioneer in gene therapies, brings over 30 years of experience, including his role in Orchard’s US$477 million acquisition and successful regulatory approvals in Europe and the U.S. His expertise will guide Eligo as it progresses toward clinical trials and expands its therapeutic pipeline.
Dr. Gaspar expressed his enthusiasm for joining Eligo, emphasizing the company's unique opportunity to apply gene editing to address severe diseases through microbiome targeting. He looks forward to collaborating with the Eligo team to advance this groundbreaking platform.
In addition, Eligo welcomed new strategic investors, including VIVES Partners and CRISPR pioneer Prof. Rodolphe Barrangou, as it advances its lead program into clinical trials for the first-ever topical CRISPR treatment for moderate to severe acne.
